The Somatropin Market, estimated at USD 4.43 Bn in 2025, is expected to exhibit a CAGR of 7.3% and reach USD 7.25 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
The key market players are focused on adopting growth strategies such as product launch as well as partnerships, which will drive the global somatropin market during the forecast period. For instance, in August 2021, Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon technologies, announced that the U.S. Food and Drug Administration (FDA) has approved SKYTROFA (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone (GH).
Global Somatropin Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a negative impact on the global somatropin market. According to a Frontiers article, patients with low growth hormone secretion present a risk factor for COVID-19, which calls for attention in order to aid in COVID-19 prevention. Additionally, Prader-Willi syndrome patients must exercise sufficient caution to reduce their risk of contracting COVID-19. Additionally, patients with Prader-Willi syndrome may not exhibit typical symptoms such a high temperature and they may also have a higher pain threshold than usual, which may cause a delay in the diagnosis of COVID-19. Turner syndrome sufferers are more likely to have a serious illness from the COVID-19 virus. The COVID-19 pandemic has put a strain on and had an influence on the global healthcare systems. For instance, in April 2022, according to a study published in the Journal of Saudi Medical Journal, among the participants who were compliant to medication before the pandemic, 92% continued to be compliant with growth hormone treatment during the pandemic, despite the huge impact that COVID-19 had on the health system. In this study, protein-rich foods were the most frequently consumed before the pandemic, and consumption increased during the pandemic while fast food intake was noted to have decreased during the pandemic. Participants reported consuming more desserts and sweetened drinks during the pandemic, with a significant increase in participants consuming vegetables and fruit during the pandemic.
Global Somatropin Market: Key Developments
In January 2021, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation and OPKO Health Inc., a medical test and medication company focused on diagnostics and pharmaceuticals, announced that the US Food and Drug Administration (FDA) has accepted for filing the initial Biologics License Application (BLA) for somatrogon, a long-acting human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD).